Pharmacy Times

JUNE 13, 2023

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

65

65

STAT

DECEMBER 6, 2023

With the buyout, AbbVie will acquire several clinical-stage molecules for Parkinson’s, schizophrenia, and epilepsy, among other disorders, many of which previously belonged to one of the company’s biggest rivals. Continue to STAT+ to read the full story…

127

127

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. The drug has shown promising efficacy and safety in a Phase Ib study for schizophrenia.

FDA 99

FDA 99

Pharmafile

JANUARY 3, 2023

Published date: 03/01/2023.

52

52

Pharmaceutical Technology

JULY 29, 2022

Schizophrenia Awareness Day, marked on 25 July, is a national observance that aims to raise awareness about this mental illness. Schizophrenia is a chronic brain disorder that affects a person’s ability to function, such as thinking and feeling. The other top sponsors can be seen in Figure 1.

98

98

STAT

MARCH 20, 2023

Karuna Therapeutics said Monday that its treatment for schizophrenia reduced psychosis reported by patients — achieving the main goal of a large clinical trial and supporting similarly positive results from previously conducted studies. Continue to STAT+ to read the full story…

FDA 98

FDA 98

STAT

MARCH 12, 2024

… Acadia Pharmaceuticals disclosed that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial , STAT tells us. The company does not intend to conduct any further clinical trials with Nuplazid.

100

100

Hospital Pharmacy Europe

APRIL 3, 2023

Schizophrenia is a psychotic disorder characterised by positive symptoms, such as hallucinations, delusions, formal thought disorders, and negative symptoms, such as paucity of speech, anhedonia, and lack of motivation. Xanomeline is a muscarinic agonist (acting at M1 and M4) and has been shown to improve all symptoms types of schizophrenia.

Hospitals 97

Hospitals FDA 97

Pharmaceutical Commerce

NOVEMBER 29, 2023

In clinical trials, KarXT (xanomeline-trospium) demonstrated a combination of strong tolerability and clinically meaningful symptom reduction in adult patients with schizophrenia.

FDA 52

FDA 52

European Pharmaceutical Review

NOVEMBER 25, 2022

If approved, paliperidone palmitate extended-release injectable suspension (LY03010) is primed as a favourable option to treat schizophrenia, due to reduced dosage requirement of a once-a-month, yet it risks being hidden in a crowded long-acting injectable (LAI) market, GlobalData warns. percent of the US schizophrenia market in 2031.

FDA 102

FDA Dosage Labelling 102

Pharmafile

DECEMBER 7, 2023

This acquisition includes Cerevel’s neuroscience pipeline of various clinical-stage and preclinical candidates with potential indications across multiple disease areas, such as schizophrenia, Parkinson’s disease (PD) and mood disorders.

69

69

Med Ed 101

JUNE 4, 2023

Originally approved as an atypical antipsychotic used for schizophrenia, or an adjunct therapy for major depressive disorder, Rexulti finds itself alone as the only medication for this indication. Earlier this month the FDA approved Rexulti (Brexpiprazole) for the treatment of agitation in patients with dementia due to Alzheimer’s.

FDA 98

FDA 98

The Checkup by Singlecare

FEBRUARY 27, 2024

It is also FDA-approved to treat schizophrenia in adults and children ages 13 and older and to treat agitation that may occur with dementia due to Alzheimer’s disease. Food and Drug Administration (FDA) as an adjunct to be used along with an antidepressant medicine to treat major depressive disorder (MDD) in adults.

Dosage 52

Dosage FDA Generic Medicine Insurance 52

Pharmaceutical Technology

MARCH 18, 2024

Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia.

40

40

PharmExec

FEBRUARY 28, 2024

Agency identified several clinical deficiencies in the study, including insufficient evidence for roluperidone in the treatment of the negative symptoms associated with schizophrenia.

FDA 40

FDA 40

Pharmaceutical Technology

MAY 1, 2023

Teva Pharmaceuticals and MedinCell have received approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone) extended-release injectable suspension to treat adult patients with schizophrenia, a chronic, progressive, and severely debilitating mental health disorder.

FDA 75

FDA 75

Pharmaceutical Technology

NOVEMBER 14, 2023

Teva Pharmaceuticals and Royalty Pharma have partnered on a clinical research programme for olanzapine LAI (TEV-‘749), for schizophrenia.

52

52

pharmaphorum

JANUARY 3, 2023

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The post Newron says pivotal treatment-resistant schizophrenia trial is a go appeared first on.

Labelling 105

Labelling 105

pharmaphorum

SEPTEMBER 1, 2021

One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Janssen is trumpeting a new version of its Invega drug that could solve that problem. ” The post FDA clears J&J’s twice-yearly Invega for schizophrenia appeared first on. .

FDA 112

FDA 112

Pharmaceutical Technology

AUGUST 12, 2022

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. million people in the UK and 2.7

FDA 141

FDA 141

STAT

MARCH 28, 2023

Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results from a new clinical trial on Tuesday that could potentially expand use of its drug to other types of mood disorders. Sales of the Intra-Cellular drug, called Caplyta, tripled last year to $249 million.

96

96

Pharmaceutical Technology

JULY 28, 2022

Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. Despite the benefits of these products, resistance surrounding the use of LAIs in schizophrenia remains, resulting in lower-than-anticipated uptake.

98

98

STAT

JANUARY 3, 2023

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial.

97

97

pharmaphorum

AUGUST 6, 2021

Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders have historically had great difficulty onboarding and retaining patients for clinical trials. In terms of poor enrolment, clinical trials investigating psychotic disorders like schizophrenia face a particular dilemma. .

Hospitals 105

Hospitals Communication 105

The Checkup by Singlecare

MARCH 8, 2024

Latuda is commonly prescribed for the treatment of schizophrenia or depression from bipolar disorder. Some clinical studies do find that there may be differences between brand and generic drugs, though. For example, a study published in 2020 compared brand-name and generic antidepressants.

Dosage 93

Dosage Insurance FDA Hospitals 93

pharmaphorum

DECEMBER 20, 2022

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will provide additional treatment options to those living with schizophrenia. Schizophrenia is one of the 15 leading causes of disability worldwide.

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

Zagociguat is under clinical development by Tisento Therapeutics and currently in Phase I for Schizophrenia.

52

52

pharmaphorum

AUGUST 8, 2022

Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The post Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT appeared first on.

FDA 52

FDA 52

pharmaphorum

SEPTEMBER 15, 2020

Boehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment for patients with schizophrenia. The companies gave little away about CT-155, which is listed on Click’s website as being in the research phase before clinical trials have begun.

FDA 100

FDA 100

Hospital Pharmacy Europe

DECEMBER 19, 2023

Healthcare professionals involved in the prescribing of aripiprazole for schizophrenia and bipolar disorder should be alert to the known risk of patients developing addictive gambling, according to a new drug safety update. In the last 14 years, there have been 69 reports, making the 2023 figures over 46% of the total.

Hospitals 59

Hospitals 59

European Pharmaceutical Review

JANUARY 5, 2024

Utilising an add-on therapy for treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals SPA has reported significant final, one-year results from its clinical trial 014/015, evaluating evenamide as an add-on therapy to antipsychotics in treatment-resistant schizophrenia (TRS).

Labelling 104

Labelling 104

pharmaphorum

DECEMBER 17, 2020

This includes CAD-9303, a NMDAr positive allosteric modulator that could be used to treat schizophrenia, and MIJ-821, a NMDAr negative allosteric modulator for depression that was licensed to Novartis in 2015. With the acquisition of Cambridge, Massachusetts-based Cadent, Novartis gains rights to a portfolio of neurology drugs.

98

98

Med Ed 101

FEBRUARY 3, 2021

Here’s a case scenario where the clinical outcome may have hinged on taking ziprasidone with or without food. KD is a 33-year-old male who was diagnosed with schizophrenia. of schizophrenia. Olanzapine led to a quick uptick […].

40

40

Pharmafile

MARCH 28, 2023

New data suggestive of clinically important response in TRS patients read more

52

52

STAT

DECEMBER 7, 2023

 With this latest deal, AbbVie will acquire several clinical-stage molecules for Parkinson’s, schizophrenia, and epilepsy, among other disorders, many of which previously belonged to one of its biggest rivals. Continue to STAT+ to read the full story…

99

99

pharmaphorum

JUNE 30, 2021

Shares in Pfizer spinout Cerevel Therapeutics have more than doubled after it reported positive early-stage results with CVL-231, a drug for schizophrenia that it thinks could have a clear side-effect profile than current therapies. The post Cerevel soars on first data for muscarinic schizophrenia drug appeared first on.

59

59

The Checkup by Singlecare

APRIL 17, 2024

For schizophrenia in adults, the starting dose is 1 mg, the recommended target dose is 2–4 mg, and the maximum dosage is 4 mg. For schizophrenia in pediatric patients ages 13–17, the starting dose is 0.5 In clinical trials, antidepressants increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults.

Dosage 52

Dosage Insurance Coverage FDA Insurance 52